ÇѸ²´ëÇб³¼º½Éº´¿ø

ÀÌâ·ü ±³¼ö

  • Àü¹®¼¾ÅÍ È£Èí±â¼¾ÅÍ
  • Áø·á°ú È£Èí±â-¾Ë·¹¸£±â³»°ú

Àü¹®Áø·áºÐ¾ß

Æó¾Ï, ¸¸¼º±âµµÁúȯ(õ½Ä, COPD), ¸¸¼º±âħ, È£Èí°ï¶õ

ÀüÈ­ ¿¹¾à 033) 240-5000
±³¼ö´Ô»çÁø

(ÁÖ°£) Áø·á½Ã°£Ç¥ (2024-05-06 ~ 2024-05-11)

Áø·á½Ã°£Ç¥
Áø·á½Ã°£ ¿ù È­ ¼ö ¸ñ ±Ý Åä
¿ÀÀü ¼¾ÅÍÁø·á
¿ÀÈÄ ¼¾ÅÍÁø·á
±³¼ö´Ô »çÁø

±âº»Á¤º¸

ÇзÂ

ÇзÂ

2000.09 ~ 2002.08¿¬¼¼´ëÇб³ ÀÇÇÐ ¼®»ç

1992.03 ~ 1998.02¿¬¼¼´ëÇб³ ÀÇÇÐ Çлç

2008.03 ~ 2011.02°­¿ø´ëÇб³ ÀÇÇÐ ¹Ú»ç

°æ·Â

°æ·Â

ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø È£Èí±â³»°ú ºÎ±³¼ö

ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø È£Èí±â³»°ú Á¶±³¼ö

Columbia University Medical Center ¿¬¼ö

úÞ)ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø Áø·áºÎ¿øÀå

úÞ)ÇѸ²´ëÇб³ Æ󿬱¸¼ÒÀå

úÞ)ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø È£Èí±â³»°ú ±³¼ö

ÇÐȸȰµ¿

ÇÐȸȰµ¿

´ëÇÑÆó¾ÏÇÐȸ Á¤È¸¿ø

´ëÇÑÁßȯÀÚÀÇÇÐȸ Á¤È¸¿ø

´ëÇѳ»°úÇÐȸ Á¤È¸¿ø

´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Á¤È¸¿ø

¼ö»óÀÌ·Â

¼ö»óÀÌ·Â

2022.06Äڷγª19 ´ëÀÀ °ø·Î ¿ì¼ö °­¿øµµÁö»ç ǥâÀå

2021.11°­¿øÀμú´ë»ó À§¿øȸ ÀÇ·áÀÎ ºÎ¹® °ø·Î»ó

2021.05Äڷγª19 ´ëÀÀ °ø·Î ¿ì¼ö º¸°Çº¹ÁöºÎÀå°ü ǥâÀå

³í¹®

1. °í»ê¼Ò¿¡ ³ëÃâµÈ ½Å»ý ¹é¼­¿Í ¼º¼÷ ¹é¼­¿¡ À־ Peroxiredoxin I°ú IIÀÇ ¹ßÇö Vol. 53. No. 1. July, 2002 °áÇÙ ¹× È£Èí±â Áúȯ

2. Rifampin ³»¼º °áÇÙÀÇ Áø´Ü¿¡¼­ INNO-LiPA °Ë»ç¹ýÀÇ ÀÓ»óÀû ÀÇ¹Ì Vol. 55, No. 4, Oct. 2003 °áÇÙ ¹× È£Èí±âÁúȯ

3. Æó¾Ï°ú »óºÎ¼ÒÈ­È£Èí±â¾ÏÀÌ µ¿¹ÝµÈ ȯÀÚÀÇ °æ¿ì ÀÓ»óÀû Ư¡ Vol. 62. No. 4. April. 2007 °áÇÙ ¹× È£Èí±â Áúȯ

4. Association of Insulin Receptor Substrate-1 G972R variant with Non-Small Cell Lung Cancer Risk Vol. 1. No. 1. December. 2006 Journal of Lung Disease

°Ç°­Á¤º¸ µ¿¿µ»ó